西藏药业(600211) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 704,221,182.53, a decrease of 22.35% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 312,919,132.01, reflecting a year-on-year increase of 3.21%[3] - The net profit after deducting non-recurring gains and losses was CNY 234,860,234.76, down 19.75% year-on-year[3] - Basic and diluted earnings per share were both CNY 1.26, a decrease of 3.45% compared to the previous year[3] - Total revenue for Q1 2024 was ¥704,221,182.53, a decrease of 22.3% compared to ¥906,936,646.41 in Q1 2023[20] - Net profit for Q1 2024 reached ¥315,241,177.60, representing an increase of 3.3% from ¥305,515,106.51 in Q1 2023[21] - Earnings per share for Q1 2024 were ¥1.26, compared to ¥1.22 in Q1 2023, reflecting a growth of 3.3%[22] Cash Flow - The net cash flow from operating activities increased by 13.67% to CNY 436,177,775.81[3] - In Q1 2024, the cash inflow from operating activities was CNY 1,111,241,958.29, an increase of 14.06% compared to CNY 974,382,793.17 in Q1 2023[24] - The net cash flow from operating activities was CNY 436,177,775.81, up 13.73% from CNY 383,734,010.64 in the same period last year[25] - The cash inflow from investment activities totaled CNY 1,044,743,172.09, compared to CNY 790,518,646.02 in Q1 2023, marking a 32.14% increase[25] - The cash inflow from financing activities was CNY 261,566,016.54, significantly higher than CNY 100,000,000.00 in Q1 2023[25] - The net cash flow from financing activities increased to CNY 259,276,631.43 from CNY 50,928,297.37 in the previous year, reflecting a growth of 409.56%[25] Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,089,480,236.95, an increase of 10.95% from the end of the previous year[3] - The total assets increased to ¥5,089,480,236.95 in Q1 2024, up from ¥4,587,357,109.81 in Q1 2023, marking a growth of 10.9%[17] - Total liabilities rose to ¥1,397,352,804.33 in Q1 2024, compared to ¥1,213,736,396.92 in Q1 2023, an increase of 15.1%[17] - The total assets as of March 31, 2024, reached CNY 4,778,751,522.76, an increase from CNY 4,360,615,008.69 at the end of 2023[29] - The total liabilities increased to CNY 861,611,028.05 from CNY 670,240,257.80, indicating a rise of 28.54%[29] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 41,484[8] - The largest shareholder, Tibet Kangzhe Enterprise Management Co., Ltd., held 32.28% of the shares[8] Investment and Wealth Management - The company has invested a total of ¥110,000,000 in bank wealth management products, with a remaining balance of ¥74,000,000[11] - The annualized yield for various bank wealth management products ranges from 0.5% to 1.85%[13][14] - The company has a total of ¥903,254,275.84 in trading financial assets as of March 31, 2024, up from ¥515,336,750.95 at the end of 2023, reflecting a significant increase of approximately 75.1%[15] - The company plans to continue its wealth management strategy, with multiple ongoing bank wealth management products totaling ¥66,000,000[13][14] - The company has not reported any overdue amounts in its wealth management investments, indicating effective cash management[11] - The company is exploring further investment opportunities in fixed income and money market products to enhance returns on idle funds[13][14] Cost Management - The company reported a decrease in research and development expenses to ¥2,920,012.24 in Q1 2024 from ¥4,473,040.54 in Q1 2023, a reduction of 34.7%[21] - The company reported a decrease in sales expenses to CNY 13,121.19 from CNY 601,436.04 in the previous year, indicating improved cost management[30] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[35]